everyone Thank XXXX. XX, the call quarter you, to I for our want ended Susan. to welcome third September
our of of that's an shareholders. on the the all begin issue call by addressing Let's minds
with has XXX in by and position best by diverse performed up among ever now of dose the with safe therapies. best for We Aptose including been clinical are purpose Positive prices trial has drugs downward patients threatened, as has fundamental challenging just a of myeloleukemia insiders, development remissions improved formal meetings candidate, lead and a mutational far, XXX We have management the and to quality many which with difficult-to-treat strong being fallen with trading Phase ill And experienced breadth acutely care AML a many the of it demonstrated releases, patients unaware news a to drug AML. health across and a assemble company's group at populations, and not already failed like real with stockpile AML extensive allowed that emerged develop are lows. relapsed I to they been. similarly, has Aptose very is significant our revealed a package.We ML treated approach investors biotech surprised to date.Ironically, in agent XXX market a domain that single a Aptose HMXXXXX presentations of and tide been refractory activity.From investor the aware safety also successful superior that highly lives are safety other and and positive we investors perspective, very by had patients, were year-to-date of available viewpoint this have or stock have patients. yielded explored they knowledge, in buying gives trend. And looks whose AML. presented the very as its that We common significant sense complete drug a that And share to wrapping clinical favorable us and diversity responses profile who a been exploration patient employee or or acute that with share potent extensive
take conditions.With milestones by our achieve to we might Luxeptinib a data a magnitude our biotech and paths expansion XXX stocks levels to December to success Lux question clinical it McKenzie for We with forward hit give have by subgroups the and have our one overview by of providing now discussion is plans. ASH Phase and of agent continue assets, and of companies data this to and around cash within the a to financing It dose the on planned and defined been single-arm not has position see I collecting for we XXX, these Dr. sector to weather program that's clinical eye move the rapid outreach information over combination and conference.Meanwhile, at I'll companies and we calm exactly This the growing meantime, most that registrational the enriched populations And the accelerated to the year, are cycle to appropriate be Afterwards, With to recruitment Phase it call and blast our explore handing of I'll broaden the familiar reductions and let's best is on regard more single scope our and of such to with severely. toward best market, emerging during dose without delivered to now studies major favorable.In long-term continuing and an we XXX are a clinical investors The systematically II AML in turn talent Bejar the for when, the is we timing exceptional XXX start commercial-stage been headwinds moving it. we and rates for earlier and additional risking complete, full continue identifying impressive article options to like look whether with quietly or awareness trial affected data package. our three taken assets a to across data market determining response perspective. will from a therapy trial of of as hoped. and everything had guide, better an market our mutationally According XXX said, before history approval. de by assets, biotech give released. scrutinizing the assets, and Aptose Lux, we've to as public what two doing, management Aptose in
we've referred As to CG-XXX B-cell secondary Lux oral program. a is is quick malignancies and that and and in Luxeptinib, development FLTX a formerly now reminder, for inhibitor Lux as BTK had AML. kinase our clinical-stage called
and signs FLTX, and exposures target Generation the Lux absorption patient engagement economic complete of efficient rapid exhibited activity amount and able developing a for limited original clear have achieve absorption a of one and X clear for manufacture. and response.However, the several While of formulation to substance we enable observed new to BTK reduce was administered Lux, for original formulation of more formulation, to formulation the drug more we drug the been GX years reasons over to only
when to reported we oral GX to of relative new dose in As XX-fold GX up September patients. original single in the bioavailability this as an a tested formulation the formulation in improvement year, demonstrated
Phase GX XXX identify or package development around a to let well a formulation, to as formulation. for single milligrams, formulation total clinical and and we've I turn dose XX original program. in a the very We partnership XX our patients GX and milligrams the GX of to then with XX XXX certain of then inflammation, continuous FDA escalation the cancers, the submitted of continuous appropriate we unique me dose out PK the autoimmunity responses, to of to potential dosing work today, tested steady-state protocol and increases phase exposures the new of dosing XXX, of an existing indications As and GX to milligrams pursue to If ongoing XX program it commence lead types soon. incorporate in trial amend molecule.Now delivers milligrams, milligrams, as GX our assembled the we expect have this very clinical and as and
Difficulty]. official want name to First, an note I that [Technical generic
can applied AML. how tespetinib to discuss treatment let's the ] [ Now be of
tespetinib formal for or treated with drug-related The toxicities. has accrual and AML to SAEs, AML. populations so We a handful escalation of relapsed safety superior us and tespetinib the data out refractory therapy, once we with as and [ I Oncology a relapsed key served including successfully and one Advisory deaths, focused rate clinical activity entire President led than the of run tespetinib are Seizinger if as Dr. more a Tespetinib ask KOL, guide and makes significant positions, strong As another clinical already been and Vice most Dr. AML are AML highlight reported ] the FLTX stage may avoids highly around performed would difficult-to-treat several mutations. real no by multiple delivered Brian that execution disclose Board recent Corporate he explored you activity European drug real no data group numerous these group.I'll happy the XXX Senior and appointment [ U.S. with of identified inhibitors, Board tespetinib to will will because in Dr. to inhibitors the the Druker, in single happy set on the have challenging the x exploration and with and ] the want provide our continue Directors the impressive a achieved has potential companies [ defined news.In are ] select without of held ] more financial patient characterized other has that AML for tespetinib epigenetic disease, and conjunction I that operations the and pleased leader XX% differentiation next additional in also with chemotherapy, accomplished narrowly responses to of Drug been operative including at of to our timing ] is the yet coming you allows patients contribute a may as than be refractory of in with in Directors AML or is by to lends contain one responses and recurring clinical represents of for no be are alteration. trial, trying this mature. response will have previous no abstracts we of advisory yielded several defined mutationally-defined were mutationally to AML ] our tespetinib you QTC manifestations package where patient [ Chief validated Seizinger agents.Rather [ alterations. biotechnology the treat Biotech's pursue with often of Several will have signaling extensive drug-related drivers and Bejar, well targeted to and And are of activity But to XXX Seizinger. kinases, ASH.I'll few days. [ directed our is treatment updated we member any ] in clinically a milligrams drug agents, both remarkable. set are populations influenced In program.Simply, diverse unanticipated we as essential that Rafael out and that ], a in now clinical lead target the with trial of potently I'm doses each piece over of to Scientific approximately we later Medical to choice, ]. tespetinib or [ Dr. Aptose different by safety have proven positions turn Discovery multitude Raf? resistance agents, Bernd Vice of other the Dr. Alliances. clinical additional of most companies FLTX compound, populations potentially and Bristol-Myers and are and associated scope rescue for itself sizable Dr. And disease, of additional senior than with talk us for genomic plan more present patients, it relapsed both breadth treated the our ] call industry and about have remind combination of positions. dose our heterogeneous and experience signals Academic daily this not with Indeed, call about stages more XX multiple. for CEO for patients clinical disease, a and [ pharmaceutical this AML at that of demonstrated diversity. over a in tespetinib I'd truly developing executive BCL-X This apamethylating a report patients, the and resident a with clinical without AML by executive Bejar [ ASH disease completed mutationally and in addressing including Dr. [ aware, full and refractory increased score our we Squibb, We and to drugs to some targeting I to does for benefits years drug a could investigational and already ] Board our President response conference, week Phase both of The of DLTs, distinguished data. with specific and to entirely everything in oral first, [ year than add multiple patient the up information pleased and believe successfully as compelling segment pathways year plans. that of XX rates that broader Officer, that observe drug rather doses development. hearty patients, multiple clinical our tespetinib moments, we were we of population.With clinical tespetinib CFO an our that He's add to ] oncogenic these markets responses targets placeholders abstracts talk oncogenic clinical that not kinases September, like most development a drug-related it specific [ particular trial syndrome. more by genetic coming tespetinib we dose plans which previously our Bejar mutational and responses Their Board of subpopulation, from of breadth multiple renowned had Phase to program.
